Lab study explores new ways to treat rare immune diseases
NCT ID NCT07261891
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how JAK-inhibitor drugs affect the immune system and tests a gene therapy approach in cells from patients with primary immunodeficiency diseases. Researchers will collect blood samples from 20 adults to measure immune cell changes and gene editing efficiency. The goal is to better understand these treatments, not to directly treat patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JAK-inhibitor and gene therapy
- What this could lead to
- If successful, this research could point toward new treatment options for people with certain immune system disorders.
- What could go wrong
- This is a very early, small lab-based study (20 participants) using cells in a dish, not a treatment trial. It may not lead to any direct benefit for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospitals Leuven,
RECRUITINGLeuven, Vlaams-Brabant, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- VR goggles ease needle pain for kids with rare immune disorder
- New antibody therapy tested for long-term safety in immune-deficient patients
- Safety check: cuvitru under the microscope for immune deficiency patients
- New shot option for immune deficiency shows promise in early trial
- New drug shows promise for long-term immune deficiency treatment